Salvage Radiopeptide Therapy of Advanced Castrate-Resistant Prostate Cancer with Lutetium-177-Labeled Prostate-Specific Membrane Antigen: Efficacy and Safety in Routine Practice

Kesavan, M.R.; Turner, J. Harvey; Meyrick, Danielle; Yeo, Sharon; Cardaci, Giuseppe; Lenzo, Nat

doi:10.1089/cbr.2017.2403

Cited by 25 publications

(18 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…On the other hand, Ferdinandus et al [24] evaluated 40 patients receiving one cycle of [ 177 Lu]Lu-PSMA with a mean dose of 6.0 GBq (range: 4.1-7.1 GBq) and a mean activity of 78.5 MBq/kg of body weight and demonstrated that PSA response was independent of these factors. Also, in other studies, the cumulative activity was not predictive of PSA response [28,50] or OS [48].…”

Section: Psa Declinementioning

confidence: 72%

“…Likewise, Kesavan et al [50] studied 20 progressive mCRPC patients with a mean prescribed activity of 5.5 GBq per patient. They showed that patients receiving three cycles of therapy were statistically more likely to experience ≥ 50% reduction in PSA compared to those treated with one, two, or four cycles (P < 0.0001) [50].…”

Section: Psa Declinementioning

confidence: 99%

“…They have a better outcome than those with metastasis in other organs [58]. Multiple studies have reported that the presence of lymph node metastasis does not impact the outcome (including PSA response or survival) after [ 177 Lu]Lu-PSMA RLT [4,24,28,30,38,39,50,55]. Noteworthy, the studies rarely have evaluated the patients with lymph node-only metastasis [50].…”

Section: Lymph Node Metastasismentioning

confidence: 99%

See 2 more Smart Citations

Factors predicting biochemical response and survival benefits following radioligand therapy with [177Lu]Lu-PSMA in metastatic castrate-resistant prostate cancer: a review

Manafi‐Farid

Harsini

Saidi

et al. 2021

Eur J Nucl Med Mol Imaging

View full text Add to dashboard Cite

Background Prostate cancer (PC) is one of the most common cancers in men. Although the overall prognosis is favorable, the management of metastatic castration-resistant prostate cancer (mCRPC) patients is challenging. Usually, mCRPC patients with progressive disease are considered for radioligand therapy (RLT) after exhaustion of other standard treatments. The prostate-specific membrane antigen (PSMA) labeled with Lutetium-177 ([177Lu]Lu-PSMA) has been widely used, showing favorable and successful results in reducing prostate-specific antigen (PSA) levels, increasing quality of life, and decreasing pain, in a multitude of studies. Nevertheless, approximately thirty percent of patients do not respond to [177Lu]Lu-PSMA RLT. Here, we only reviewed and reported the evaluated factors and their impact on survival or biochemical response to treatment to have an overview of the potentialprognostic parameters in [177Lu]Lu-PSMA RLT. Methods Studies were retrieved by searching MEDLINE/PubMed and GoogleScholar. The search keywords were as follows: {(“177Lu-PSMA”) AND (“radioligand”) AND (“prognosis”) OR (“predict”)}. Studies discussing one or more factors which may be prognostic or predictive of response to [177Lu]Lu-PSMA RLT, that is PSA response and survival parameters, were included. Results Several demographic, histological, biochemical, and imaging factors have been assessed as predictive parameters for the response to thistreatment; however, the evaluated factors were diverse, and the results mostly were divergent, except for the PSA level reduction after treatment, which unanimously predicted prolonged survival. Conclusion Several studies have investigated a multitude of factors to detect those predicting response to [177Lu]Lu-PSMA RLT. The results wereinconsistent regarding some factors, and some were evaluated in only a few studies. Future prospective randomized trials are required to detect theindependent prognostic factors, and to further determine the clinical and survival benefits of [177Lu]Lu-PSMA RLT.

show abstract

Section: Psa Declinementioning

confidence: 72%

Section: Psa Declinementioning

confidence: 99%

Section: Lymph Node Metastasismentioning

confidence: 99%

See 1 more Smart Citation

Factors predicting biochemical response and survival benefits following radioligand therapy with [177Lu]Lu-PSMA in metastatic castrate-resistant prostate cancer: a review

Manafi‐Farid

Harsini

Saidi

et al. 2021

Eur J Nucl Med Mol Imaging

View full text Add to dashboard Cite

show abstract

“…In mCRPC patients who previously failed in treatments like chemotherapy, 177 Lu-PSMA RLT has been shown to increase the progression-free survival in 40-70% of patients by decreasing the levels of PSA, tumor volume, and activity. [18][19][20][21][22][23][24] This treatment is well-tolerated due to its minimal or moderate side-effects. In smaller studies, targeted alpha therapy using 225 Ac-PSMA showed decreased levels of PSA, tumor volumes and activity in patients who failed the 177 Lu-PSMA therapy.…”

Section: Variants Of 68 Ga-psma-11mentioning

confidence: 99%

Impact of the 68Ga Prostate-Specific Membrane Antigen (68Ga-PSMA) PET/CT on the Management of Prostate Cancer

Gurunath¹,

Salunke²,

Komittishetty³

2020

Journal of Exploratory Research in Pharmacology

View full text Add to dashboard Cite

This review discusses the efficiency and sensitivity of 68 Ga-labelled prostate-specific membrane antigen (PSMA) positron emission tomography (PET)/computed tomography (CT) imaging in comparison to other radiotracers and imaging techniques. It also conveys its impact on the treatment or management of prostate cancer patients. PSMA, observed in almost all prostate cancer cells, is used for staging and treatment, due to its high multiplication in this cancer when compared to normal tissues. PSMA PET/magnetic resonance imaging (MRI) has applications in the management of prostate cancer. Though PSMA PET/MRI has yielded preliminary results, it is still studied as an imaging biomarker for tumor responses. PSMA-PET/CT is known for its highly sensitive resolution, as it lights up only the parts harboring prostate cancer or tumor cells and not any other kind of lesion. Therefore, 68 Ga-PSMA-PET imaging is chosen over other variants of 68 Ga-PSMA-11, such as 177 Lu-PSMA or 225 Ac-PSMA, and it is used for its greater ability to detect metastatic sites in patients with biochemical recurrence and low serum prostate-specific antigens values. The efficacy of 68 Ga-PSMA PET/CT also allows for estimation of oligometastases, as it supports the design of therapeutic trials in measuring long-term effects in patients. Finally, 68 Ga-PSMA PET/ CT is effective in identifying recurrence localization and, hence, permits the ability to choose the best therapeutic strategy as early as possible.

show abstract

“…68 Ga-PSMA PET/CT has been used over the last 4–5 years in its theranostic capacity to guide therapy using the labelled therapeutic radiopharmaceutical 177 Lu-PSMA ( Figure 6 ). This targeted radiopeptide therapy has been shown to decrease PSA levels, objectively decrease tumor volumes and tumor activity and improve progression free survival in 40–70% of mCRPC patients who have failed previous treatment modalities including chemotherapy [ 2 , 115 , 116 , 117 , 118 , 119 , 120 ]. This has been shown to be a well-tolerated treatment with minimal acute or medium term side-effects, similar to our experience with 177 Lu-DOTATATE in NET’s.…”

Section: New Clinical Applicationsmentioning

confidence: 99%

Review of Gallium-68 PSMA PET/CT Imaging in the Management of Prostate Cancer

Meyrick²,

2018

Self Cite

View full text Add to dashboard Cite

Over 90% of prostate cancers over-express prostate specific membrane antigen (PSMA) and these tumor cells may be accurately targeted for diagnosis by 68Ga-PSMA-positron emission tomography/computed tomography (68Ga-PSMA-PET/CT) imaging. This novel molecular imaging modality appears clinically to have superseded CT, and appears superior to MR imaging, for the detection of metastatic disease. 68Ga-PSMA PET/CT has the ability to reliably stage prostate cancer at presentation and can help inform an optimal treatment approach. Novel diagnostic applications of 68Ga-PSMA PET/CT include guiding biopsy to improve sampling accuracy, and guiding surgery and radiotherapy. In addition to facilitating the management of metastatic castrate resistant prostate cancer (mCRPC), 68Ga-PSMA can select patients who may benefit from targeted systemic radionuclide therapy. 68Ga-PSMA is the diagnostic positron-emitting theranostic pair with the beta emitter Lutetium-177 PSMA (177Lu-PSMA) and alpha-emitter Actinium-225 PSMA (225Ac-PSMA) which can both be used to treat PSMA-avid metastases of prostate cancer in the molecular tumor-targeted approach of theranostic nuclear oncology.

show abstract

Salvage Radiopeptide Therapy of Advanced Castrate-Resistant Prostate Cancer with Lutetium-177-Labeled Prostate-Specific Membrane Antigen: Efficacy and Safety in Routine Practice

Abstract: Lu-PSMA I&T radioimmunotherapy of progressive mCRPC is safe and effective with three cycles being the potential optimal number for determining long-term disease response.

Cited by 25 publications

References 35 publications

Factors predicting biochemical response and survival benefits following radioligand therapy with [177Lu]Lu-PSMA in metastatic castrate-resistant prostate cancer: a review

Factors predicting biochemical response and survival benefits following radioligand therapy with [177Lu]Lu-PSMA in metastatic castrate-resistant prostate cancer: a review

Impact of the 68Ga Prostate-Specific Membrane Antigen (68Ga-PSMA) PET/CT on the Management of Prostate Cancer

Review of Gallium-68 PSMA PET/CT Imaging in the Management of Prostate Cancer

Contact Info

Product

Resources

About